Avinger (NASDAQ:AVGR) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Avinger (NASDAQ:AVGR) in a research note issued to investors on Wednesday. The firm issued a hold rating on the medical device company’s stock.

Separately, HC Wainwright restated a buy rating and issued a $5.00 target price on shares of Avinger in a research note on Thursday, March 21st.

Avinger Stock Down 5.1 %

Shares of AVGR stock opened at $3.73 on Wednesday. The business has a 50 day moving average of $3.46 and a two-hundred day moving average of $3.34. Avinger has a 52 week low of $2.50 and a 52 week high of $18.00. The company has a market cap of $5.93 million, a P/E ratio of -0.14 and a beta of 1.26.

Avinger (NASDAQ:AVGR) last issued its earnings results on Wednesday, March 20th. The medical device company reported ($3.93) EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($4.57). The business had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.52 million. Analysts expect that Avinger will post -2.08 EPS for the current fiscal year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.